Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

1.4%

1 terminated/withdrawn out of 72 trials

Success Rate

87.5%

+1.0% vs industry average

Late-Stage Pipeline

10%

7 trials in Phase 3/4

Results Transparency

0 of 7 completed trials have results

Key Signals

29 recruiting

Enrollment Performance

Analytics

Phase 2

20(32.8%)

N/A

19(31.1%)

Phase 1

12(19.7%)

Phase 4

6(9.8%)

Early Phase 1

3(4.9%)

Phase 3

1(1.6%)

61Total

Phase 2(20)

N/A(19)

Phase 1(12)

Phase 4(6)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (72)

Showing 20 of 72 trials

NCT07167342Phase 4Not Yet Recruiting

The Effect of Oral Clostridium Butyricum on the Recurrence After Colonoscopic Resection of Colorectal Adenoma

Role: collaborator

NCT07481656Phase 4Not Yet Recruiting

Effects of Recombinant Human Growth Hormone in Elderly Patients With Moderate to Severe Acute Brain Injury (GH-ABI-RCT)

Role: collaborator

NCT05376111Phase 2Recruiting

Study of Venetoclax Combined With Azacitidine Regimen in Newly Diagnosed T-ALL Patients

Role: collaborator

NCT06220162Phase 2Recruiting

VAC Regimen for AML Patients Who Failed to Response to VA Regimen

Role: collaborator

NCT07462676Not ApplicableNot Yet Recruiting

Simultaneous Vs Staged VPS and CP :A Multi-cnter RCT.

Role: collaborator

NCT06765590Not ApplicableRecruiting

Bioequivalence Study of Paclitaxel for Injection (Albumin Bound) in Subjects With Breast Cancer

Role: collaborator

NCT06061614Early Phase 1Recruiting

Safety and Efficacy Study of NGGT002 in PKU Adult Subjects

Role: lead

NCT07394309Phase 1Not Yet Recruiting

Study of Hydroxynidone Capsules in Patients With Hepatic Impairment and Matched Healthy Controls

Role: collaborator

NCT07402525Not ApplicableRecruiting

Postoperative Radiotherapy for Early-stage Oral Tongue Squamous Cell Carcinoma Patients With Risk Factors: a Prospective, Multicenter, Randomized Controlled, Open-labelled Trial

Role: collaborator

NCT07330882Not ApplicableEnrolling By Invitation

Health Behavior Management Program for Patients With Coronary Heart Disease

Role: lead

NCT06298071Phase 1Recruiting

A Phase Ib Clinical Trial of Peguricase for Injection With Methotrexate in Patients With Uncontrolled Gout.

Role: collaborator

NCT05657652Not ApplicableRecruiting

CAV Regimen for R/R Ph- B-ALL

Role: collaborator

NCT05657639Phase 2Recruiting

CAV Regimen for R/R AML

Role: collaborator

NCT07300215Phase 2Not Yet Recruiting

An Exploratory Study on Individualized Neoadjuvant Treatment Regimens for Early HR+/HER2+ Breast Cancer

Role: lead

NCT05901974Phase 2Recruiting

Venetoclax Combined With Azactidine in the Treatment of ALAL

Role: collaborator

NCT05940961Phase 2Recruiting

Inotuzumab Ozogamicin in the Treatment of MRD+ After HSCT of ALL

Role: collaborator

NCT05566054Phase 2Recruiting

Venetoclax and Azacitidine Combined With Chidamide (VAC) for the Treatment of Newly Diagnosed Acute Monocytic Leukemia

Role: collaborator

NCT06532552Phase 2Recruiting

Comparison of VA (Venetoclax, Azacitidine), VACl (VA, Cladribine), VACh (VA, Chidamide), and Alternating VACl/VACh in Newly Diagnosed Acute Myeloid Leukemia

Role: collaborator

NCT07150624Phase 4Recruiting

The Treatment of Liver Injury After Liver Resection With Polyene Phosphatidylcholine

Role: collaborator

NCT05470777Phase 2Recruiting

CD22/CD19 CAR-T and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL

Role: collaborator